肝脏黏度:病理意义及其在临床实践中评估代谢功能障碍相关脂肪性肝病严重程度的价值
研究纳入275例疑似MASLD行肝活检患者,用2D-SWE测量肝脏黏度,在推导集(Angers大学医院,n=183)和验证集(Besançon大学医院,n=92)中构建并验证MASH评分(BMI、性别、肝脏黏度)。MASH评分诊断MASH的AUROC在推导集为0.85,验证集为0.82;与2D-SWE联合诊断纤维化性MASH的AUROC在推导集为0.81,验证集为0.78。
要点
- 肝脏黏度由2D-SWE测得,与BMI、性别组合成MASH评分,可无创诊断MASH。
- MASH评分排除阈值为≤0.578、纳入阈值为≥0.863,验证集敏感度84%、特异度96%。
- MASH评分联合同一设备上的2D-SWE可识别需要药物治疗的纤维化性MASH患者。
核心结论
- 基于超声的MASH评分能准确诊断MASH,与同一设备可用的2D-SWE联合可准确识别需要药物治疗的MASLD患者。
研究设计与样本
- 研究纳入275例因疑似MASLD行肝活检并接受2D-SWE肝脏黏度测量的患者,推导集来自Angers大学医院(n=183),验证集来自Besançon大学医院(n=92)。
诊断标准与关键数值
- MASH定义为肝活检示脂肪变伴小叶内炎症和气球样变;MASH评分在推导集的AUROC为0.85(95%CI:0.79-0.92),验证集为0.82(95%CI:0.73-0.92)。
临床应用与阅片要点
- 推导集确定的排除阈值(≤0.578)和纳入阈值(≥0.863)在验证集分别提供84%敏感度和96%特异度;2D-SWE诊断显著纤维化F≥2的AUROC为0.82(95%CI:0.77-0.88);MASH评分联合2D-SWE诊断纤维化性MASH的AUROC在推导集为0.81(95%CI:0.74-0.87),验证集为0.78(95%CI:0.69-0.87)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVES: The non-invasive diagnosis of metabolic dysfunction-associated steatohepatitis (MASH) is a critical unmet need. Liver viscosity is a new ultrasound measurement based on 2D-Shear Wave Elastography (2D-SWE). We aimed to characterize the association between liver viscosity and histologic component, and to determine whether this new parameter can improve the non-invasive diagnosis of MASH.
MATERIALS AND METHODS: Two hundred seventy-five patients undergoing liver biopsy for suspected MASLD were included and had 2D-SWE with liver viscosity measurements. Patients were enrolled in Angers University Hospital (derivation set, n = 183) and Besançon University Hospital (validation set, n = 92) centers. MASH was defined on liver biopsy as the presence of steatosis with lobular inflammation and ballooning.
RESULTS: Independent predictors of MASH in the derivation set (BMI, gender, liver viscosity) were combined into the MASH score. The AUROC of the MASH score was 0.85 [95% CI: 0.79-0.92] in the derivation set and 0.82 [95% CI: 0.73-0.92] in the validation set. The rule-out (≤ 0.578) and rule-in (≥ 0.863) thresholds determined in the derivation set provided, respectively, 84% sensitivity and 96% specificity in the validation set. The AUROC of 2D-SWE for significant fibrosis F ≥ 2 was 0.82 [95% CI: 0.77-0.88]. The MASH score was combined with 2D-SWE to diagnose fibrotic MASH, which is the indication for pharmacological therapy. The AUROC of the combination was 0.81 [95% CI: 0.74-0.87] in the derivation set and 0.78 [95% CI: 0.69-0.87] in the validation set.
CONCLUSION: The ultrasound-based MASH score accurately diagnoses MASH. Combined with 2D-SWE available in the same device, it accurately identifies MASLD patients who require pharmacological therapy.
KEY POINTS: Question The transition from MASLD to MASH is critical, yet no simple non-invasive diagnostic method currently exists for accurately identifying MASH patients. Findings Liver viscosity measured by 2D-SWE, combined with BMI and gender, provides a score (MASH score) that accurately diagnoses MASH. Clinical relevance This ultrasound-based MASH score offers a practical and widely accessible tool to identify patients with MASH or fibrotic MASH requiring follow-up and treatment, improving management of MASH.
引用
- Paisant A, Roux M, Calame P, et al. Liver viscosity: pathological significance and interest for the assessment of MASLD severity in clinical practice. Eur Radiol. 2025. PMID: 41258457. doi:10.1007/s00330-025-12142-7
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。